Takeda

News

Takeda plans filings for Sotyktu rival on new psoriasis data

Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

Takeda builds in cancer with monster $11.4bn Innovent deal

Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.

News

Three more pharmas join OpenFold3 AI consortium

Bristol Myers Squibb, Takeda, and Astex have joined a consortium working on refining the OpenFold structure prediction platform with industry data.

News

Takeda's narcolepsy programme gets back on track

Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.

News

NICE relents on Takeda colorectal cancer drug Fruzaqla

Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.

Takeda plans filings for Sotyktu rival on new psoriasis data

Alkermes breaks new ground in narcolepsy with orexin drug

Takeda builds in cancer with monster $11.4bn Innovent deal

Three more pharmas join OpenFold3 AI consortium

Takeda's narcolepsy programme gets back on track

NICE relents on Takeda colorectal cancer drug Fruzaqla

BioMarin ends year with $4.8bn play for Amicus

How to meet your physicians where they are online

Takeda

Editor's Picks